Wall Street analysts forecast that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will report sales of $9.83 million for the current fiscal quarter, Zacks reports. Five analysts have made estimates for BioDelivery Sciences International’s earnings. The lowest sales estimate is $8.99 million and the highest is $10.93 million. BioDelivery Sciences International posted sales of $3.93 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 150.1%. The firm is expected to report its next quarterly earnings results on Friday, March 16th.
On average, analysts expect that BioDelivery Sciences International will report full year sales of $9.83 million for the current year, with estimates ranging from $37.01 million to $60.40 million. For the next fiscal year, analysts forecast that the business will post sales of $47.29 million per share, with estimates ranging from $42.70 million to $54.67 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow BioDelivery Sciences International.
A number of brokerages recently weighed in on BDSI. Piper Jaffray Companies set a $4.00 price objective on BioDelivery Sciences International and gave the stock a “buy” rating in a report on Sunday, October 22nd. HC Wainwright set a $5.00 price objective on BioDelivery Sciences International and gave the stock a “buy” rating in a report on Monday, November 27th. Seaport Global Securities began coverage on BioDelivery Sciences International in a report on Friday, January 26th. They set a “buy” rating and a $5.00 price objective on the stock. Finally, Roth Capital set a $5.00 price objective on BioDelivery Sciences International and gave the stock a “buy” rating in a report on Monday, November 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $4.38.
A number of institutional investors have recently bought and sold shares of BDSI. Wells Fargo & Company MN grew its holdings in BioDelivery Sciences International by 138.2% in the third quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 20,599 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in BioDelivery Sciences International in the third quarter valued at $116,000. Advisor Group Inc. grew its holdings in BioDelivery Sciences International by 42.1% in the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after purchasing an additional 13,341 shares during the last quarter. Northern Trust Corp grew its holdings in BioDelivery Sciences International by 0.9% in the second quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock valued at $394,000 after purchasing an additional 1,203 shares during the last quarter. Finally, Krilogy Financial LLC lifted its position in shares of BioDelivery Sciences International by 28.8% in the third quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock valued at $395,000 after acquiring an additional 30,000 shares in the last quarter. 44.16% of the stock is currently owned by institutional investors.
BioDelivery Sciences International (BDSI) opened at $2.20 on Monday. BioDelivery Sciences International has a twelve month low of $1.55 and a twelve month high of $3.60. The firm has a market capitalization of $125.74, a price-to-earnings ratio of 24.44 and a beta of 0.50. The company has a current ratio of 1.28, a quick ratio of 1.07 and a debt-to-equity ratio of 1.89.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.